Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Related Articles
Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024
Company to highlight how its ECG-AI™ algorithms enable earlier cardiovascular disease detectionNovember 14, 2024
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022
Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection
FIERCE Healthcare: Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses…April 13, 2021
Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease
NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosisDecember 16, 2022